Skip to content

Psilocybin for depression: all studies

Page 31 of 49: studies 301 to 310 of 490, newest first. Back to the psilocybin for depression overview

Research

Psilocybin's Emerging Role in Combating Depressive Disorder

Journal of Education Health and Sport August 8, 2023 Anna Jaremek, Joanna Kępa, Norbert Kandefer et al.

In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select species of fungi, as a prospective avenue for depression treatment. Depression, a widespread psychological malady affecting countless individuals across the globe, often proves stubborn against existing treatment modalities, necessitating exploration...

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

European Neuropsychopharmacology August 7, 2023 Natacha Perez, Florent Langlest, Luc Mallet et al. 85 citations

Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. Following our protocol (CRD 42022220190) multiple electronic databases were searched from their inception until February 2023, to identify...

A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression

International Journal of Molecular Sciences August 7, 2023 Alexander Pilozzi, Simmie Foster, David Mischoulon et al. 16 citations

Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using...

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.

Journal of Affective Disorders August 1, 2023 Richard J. Zeifman, Anne C Wagner, Candice M Monson et al. 56 citations

Psilocybin therapy is receiving attention as a mental health intervention with transdiagnostic potential. In line with psychotherapeutic research, qualitative research has highlighted the role of reductions in experiential avoidance (and increases in connectedness) within psilocybin therapy. However, no quantitative research has examined experiential avoidance as a mechanism underlying...

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis

Psychiatry Research July 23, 2023 Otto Simonsson, Per Carlbring, Robin Carhart-Harris et al. 24 citations

We conducted a meta-analysis using individual participant data from three, two-dose psilocybin trials for depression (N = 102) with the aim of assessing the risk of symptom worsening. Clinically significant symptom worsening occurred for a minority of participants in the psilocybin and escitalopram conditions (∼10%) and for a majority of participants in the waitlist condition (63.6%). Using...

DOI: 10.1016/j.psychres.2023.115349 (opens in new tab) Meta-analysis Psilocybin therapy Clinical depression treatment Psychedelic medicine +2

Psilocybin Therapy for Major Depressive Disorder: A Systematic Review

Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal July 19, 2023 Kaden Venugopal 1 citation

Introduction: Major depressive disorder (MDD) is a prevalent and complex mood disorder. Its psychotherapies often involve delayed treatment-response times, while its pharmacotherapies can cause unwanted side effects. In recent years, there has been a resurgence in psychedelic research with a specific interest in the potential of psilocybin for treating MDD. Therefore, this systematic review was...

DOI: 10.26685/urncst.489 (opens in new tab) Psilocybin Peer review Medical education Library science +1

Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression – CORRIGENDUM

Psychological Medicine July 19, 2023 Brandon Weiss, Induni Ginige, Lu Shannon et al. 1 citation

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.

Psilocybin-assisted psychotherapy for cancer-related anxiety and depression

International Journal of Gynecological Cancer July 18, 2023 Dan Yaniv, L. Ramondetta, L. Cohen et al.

Women with gynecologic cancers face various physical and psychological challenges throughout their treatment journey. Late stages associated with poor prognosis, along with chronic side effects of treatment, often leave women with existential uncertainty stemming from unpredictable disease trajectory and continuous fear of death. Recently, a patient in her late 30s (JN) with endstage ovarian...

Increased low-frequency brain responses to music after psilocybin therapy for depression.

Journal of Affective Disorders July 15, 2023 Matthew B. Wall, Cynthia Lam, Natalie Ertl et al. 36 citations

Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therapy (PT) methods incorporate music as a key element. Music is an effective emotional/hedonic stimulus that could also be useful in assessing changes in emotional responsiveness following PT. Brain responses to music were assessed before and after PT using...